David Swinney has over 25 years of industrial drug discovery experience (Roche, Syntex, iRND3) working to identify promising leads, clinical candidates and effective mechanisms of drug action that address unmet medical needs. He has a PhD in medicinal chemistry from the University of Washington, Seattle, and expertise in drug discovery, drug discovery strategies, assay development and screening, enzymology, pharmacology and binding kinetics. Dave is currently at the non-profit Institute for Rare and Neglected Diseases Drug Discovery in Mountain View, CA, aka iRND3, (www.irnd3.org) working to help discover new medicines for rare and neglected diseases.
Saturday, January 25, 2020
8:30 AM – 4:30 PM